Foods to Avoid During Prostate Cancer

The foods you take in play a role in the general wellness of the prostate gland. Some foods like soybean products, tomato plants, beans and cruciferous vegetables are suggested to keep it healthy, while other product needs to be prevented. There are many regularly eaten foods which have been associated with greater chances of prostatic problems like cancer of the prostate. By staying away from these foods you could reduce risks.

High-Fat Products

Diet routines containing a significant amount of high-fat Products can adversely impact the health condition of your prostatic gland. Consuming foods loaded with saturated fats like red meats and whole fat dairy products increases your danger of developing prostatic adenocarcinoma. To lessen the danger make sure you keep away from these and maintain your saturated fat consumption to 10% of your daily calories. Most of your fat calories must originate from unsaturated fats.

Low-Fiber Products

Consuming products that have very little to no dietary fiber increases your danger of prostatic problems. Abstain from low-fiber foods like white bread, white pasta, white rice, white flour and white sugar. Fast food choices are frequently low in fiber and must be averted to maintain a healthy prostatic gland. On the other hand, a high-fiber diet plan often helps lower risk of developing prostatic adenocarcinoma.

Milk

Dairy products have been associated with increased risks of prostatic adenocarcinoma. Milk boosts the level of insulin-like growth factor in your blood and this particular boost can promote the development of prostatic adenocarcinoma cells. Also, the high calcium quantities in milk can result in a reduction in vitamin D, and decreased vitamin D amounts are connected with prostatic cancer. To decrease your risk substitute your dairy milk with soy milk or give up the use of milk completely.

High Calcium Products

Diet routines which are frequently high in calcium have been associated with elevated risks of prostatic adenocarcinoma. To prevent prostatic gland issues you need to maintain your regular calcium consumption less than 1,500 mg a day. Should you take a multivitamin pill be sure that the calcium amount is not raising your calcium amounts above what's going to raise your risk of prostatic problems.

Alcohol

Alcohol consumption must be kept to average amounts to keep the prostate gland healthy. Consistent heavy drinking increases your threat of developing the more aggressive types of cancer of the prostate. Avoid consuming over 2 alcohol-based drinks each day; this can also help you prevent an increased prostate.

Processed Foods

Highly processed foods usually consist of increased levels of nutritionally poor calories. Consuming these regularly can result in unwanted fat gain, that could raise your threat of prostatic adenocarcinoma along with other prostate issues like erectile dysfunction. Additionally, stuffing up on processed foods might leave you lacking of a number of the nutrients and vitamins that prevent cancer of the prostate, like lycopene and phytoestrogens.

I have a friend who has prostate cancer and I went with him to see his doctor. He asked his doctor regarding foods he wanted to eat, and his doctor gave him the list of foods he should avoid. It was a very comprehensive list but very helpful. This natural treatment for prostate cancer can truly aid in your healing.

View the original article here

How the specific chemical Modifications to turn genes on and off voltage during the beginning of the development - and how these mechanisms are disrupted in Cancer

Main Category: Cancer / Oncology
Also Included In: Genetics
Article Date: May 2013 13 - 1:00 PDT Current ratings for:
How Precise Chemical changes Turn Genes On And Off During Early Development - And How Those Mechanisms Are Disrupted In Cancer

A large, multi-institutional research team involved in the NIH Epigenome Roadmap Project has published a sweeping analysis in the current issue of the journal Cell on how genes are turned on and off to direct early human development. Led by Bing Ren of the Ludwig Institute for Cancer Research, Joseph Ecker of The Salk Institute for Biological Studies and James Thomson of the Morgridge Institute for Research, the scientists also describe novel genetic phenomena likely to play a pivotal role not only in the genesis of the embryo, but that of cancer as well. Their publicly available data, the result of more than four years of experimentation and analysis, will contribute significantly to virtually every subfield of the biomedical sciences.

After an egg has been fertilized, it divides repeatedly to give rise to every cell in the human body - from the patrolling immune cell to the pulsing neuron. Each distinct functionally generation of cells subsequently differentiates itself from its predecessors in the developing embryo by expressing only a selection of its full complement of genes, while actively suppressing others. "By applying large-scale genomics technologies," explains Bing Ren, PhD, Ludwig Institute member and a professor in the Department of Cellular and Molecular Medicine at the UC San Diego School of Medicine, "we could explore how genes across the genome are turned on and off as embryonic cells and their descendant lineages choose their fates, determining which parts of the body they would generate."

One way cells regulate their genes is by DNA methylation, in which a molecule known as a methyl group is tacked onto cytosine - one of the four DNA bases that write the genetic code. Another is through scores of unique chemical modifications to proteins known as histones, which form the scaffolding around which DNA winds in the nucleus of the cell. One such silencing modification, called H3K27me3, involves the highly specific addition of three methyl groups to a type of histone H3 named. "People have generally not thought of these two 'epigenetic' changes as being very different in terms of their function," says Ren.

The current study puts an end to that notion. The researchers found in their analysis of those changes across the genome - referred to, collectively, as the epigenome - that master genes that govern the regulation of early embryonic development tends largely to be switched off by H3K27me3 histone methylation. Meanwhile, those that orchestrate the later stages of cellular differentiation, when cells become increasingly committed to specific functions, are primarily silenced by DNA methylation.

"You can sort of glean the logic of animal development in this difference," says Ren. "Histone methylation is relatively easy to reverse. But reversing DNA methylation is a complex process, one that requires more resources and is much more likely to result in potentially deleterious mutations. "So it makes sense that histone methylation is largely used to silence master genes that may be needed at multiple points during development, while DNA methylation is mostly used to switch off genes at later stages, when cells have already been tailored to specific functions, and those genes are less likely to be needed again."

The researchers also found that the human genome is peppered with more than 1,200 large regions that are consistently devoid of DNA methylation throughout development. It turns out that many of the genes considered master regulators of development are located in these regions, which the researchers call DNA methylation valleys (DMVs). Further, the team found that the DMVs are abnormally methylated in colon cancer cells. While it has long been known that aberrant DNA methylation plays an important role in various cancers, these results suggest that changes to the cell's DNA methylation machinery itself may be a major step in the evolution of tumors.

Further, the researchers catalogued the regulation of DNA sequences known as enhancers, which, when activated, boost the expression of genes. They identified more than 103,000 possible enhancers and charted their activation and silencing in six cell types. Researchers will in all likelihood continue to sift through the data generated by this study for years to come, putting the epigenetic phenomena into biological context to investigate a variety of cellular functions and diseases.

"These data are going to be very useful to the scientific community in understanding the logic of early human development," says Ren. "But I think our main contribution is the creation of a major information resource for biomedical research." "Many complex diseases have their roots in early human development."

Laboratories led by Michael Zhang, at the University of Texas, Dallas, and Wei Wang, at the University of California, La Jolla, contributed extensively to the computational analysis of data generated by the epigenetic mapping.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. The study was supported by the Ludwig Institute for Cancer Research, the NIH Epigenome Roadmap Project (U01 ES017166), NSFC 91019016, NIH R01 HG001696 (M.Q.Z.), NIH P01 GM081629 (J.A.T.), CIRM RN2-00905-1 q.b. the US Heart, Lung and Blood Institute and the American Heart Association (12POST12050080).
Ludwig Institute for Cancer Research Please use one of the following formats to quote this article in your essay, paper or report:

MLA

Ludwig Institute for Cancer Research. "How Precise Chemical changes Turn Genes On And Off During Early Development - And How Those Mechanisms Are Disrupted In Cancer." Medical News Today. MediLexicon, Intl., May 13. 2013 Web.
May 13. 2013 APA
Ludwig Institute for Cancer Research. (2013, May 13). "How Precise Chemical changes Turn Genes On And Off During Early Development - And How Those Mechanisms Are Disrupted In Cancer." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/260387.php.

Please note: If no author information is provided, the source is cited instead.

' How Precise Chemical changes Turn Genes On And Off During Early Development - And How Those Mechanisms Are Disrupted In Cancer'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Ovarian Suppression During Chemotherapy Fails to Improve Post-Treatment Menstrual Function

Among young women undergoing chemotherapy for breast cancer, use of the drug triptorelin to suppress ovarian function during treatment does not appear to improve post-treatment menstrual function. These results were published in the Journal of Clinical Oncology.???

Fertility preservation is increasingly being recognized as an important issue for young people with cancer. In premenopausal women, many chemotherapy drugs are toxic to the egg cells (oocytes) in the ovaries. If the number of remaining oocytes in the ovaries reaches a critically low point during treatment, women experience “acute ovarian failure.” This means that the ovaries stop functioning during or shortly after cancer treatment. If oocytes are lost during treatment but do not reach this critically low point, women are at risk for early menopause but may still be able to get pregnant for some time after treatment.????

Freezing embryos prior to cancer treatment is one of the most well established approaches to fertility preservation in young women, but is not always an option. One of the alternative approaches being evaluated involves the use of drugs known as gonadotropin-releasing hormone (GnRH) agonists to suppress ovarian function during chemotherapy. The hope is that this will protect the ovaries and improve post-treatment ovarian function.????

To explore the effects of the GnRH agonist triptorelin during chemotherapy for breast cancer, researchers conducted a study among premenopausal women age 44 or younger. Study participants were assigned to receive either triptorelin or a placebo. The study was originally designed to enroll 124 women, but it was stopped after only 49 women were enrolled because preliminary results indicated no benefit from triptorelin.????

Menstruation resumed in 88 percent of women in the triptorelin group and 90 percent of women in the placebo group.?Menstrual cycles resumed after a median of 5.8 months in the triptorelin group and 5.0 months in the placebo group.?

These results suggest that triptorelin does not improve post-treatment menstrual function in young breast cancer patients. Other, ongoing studies will provide more information on this topic.? ?

Premenopausal women who are interested in preserving their fertility during cancer treatment are advised to discuss their options with their physician before treatment begins.?????

Reference: Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology. Early online publication January 9, 2012.?

Posted January 13, 2012?

View the original article here